CREATE ACCOUNT

Request Registration Code

Terms of Service

All messages posted at this site express the views of the author, and do not necessarily reflect the views of the owners and administrators of this site.

By registering at this site you agree not to post any messages that are obscene, vulgar, slanderous, hateful, threatening, or that violate any laws. We will permanently ban all users who do so.

We reserve the right to remove, edit, or move any messages for any reason.

  I agree to the terms of service

FORGOT YOUR DETAILS?

NAD+ can restore age related muscle deterioration

Thursday, 21 January 2021 by System Administrator

Canstockphoto4409350

NAD+ can restore age-related muscle deterioration

The older we grow, the weaker our muscles get, riddling old age with frailty and physical disability. But this doesn't only affect the individual, it also creates a significant burden on public healthcare. And yet, research efforts into the biological processes and biomarkers that define muscle aging have not yet defined the underlying causes.

Now, a team of scientists from lab of Johan Auwerx at EPFL's School of Life Sciences looked at the issue through a different angle: the similarities between muscle aging and degenerative muscle diseases. They have discovered protein aggregates that deposit in skeletal muscles during natural aging, and that blocking this can prevent the detrimental features of muscle aging. The study is published in Cell Reports.

"During age-associated muscle diseases, such as inclusion body myositis (IBM), our cells struggle to maintain correct protein folding, leading these misfolded proteins to precipitate and forming toxic protein aggregates within the muscles," explains Auwerx. "The most prominent component of these protein aggregates is beta-amyloid, just like in the amyloid plaques in the brains of patients with Alzheimer's disease."

In the study, the scientists identify amyloid-like protein aggregates in aged muscles from different species, from the nematode C. elegans all the way to humans. In addition, they also found that these aggregates also impair mitochondrial function. Although aggregated proteins have been suggested to contribute to brain aging, this is the first time that they have been shown to contribute to muscle aging and to directly damage mitochondria. "These abnormal proteotoxic aggregates could serve as novel biomarkers for the aging process, beyond the brain and muscle," says Auwerx.

But can the formation of the protein aggregates be reversed? To answer this, the researchers fed worms the vitamin nicotinamide riboside and the antitumor agent Olaparib, both of which boost the levels of nicotinamide adenine dinucleotide (NAD+), a biomolecule that is essential for maintaining mitochondrial function, and whose levels decline during aging.

In the worms, the two compounds turned on the defense systems of the mitochondria, even when provided at advanced age. Turning on the so-called "mitochondrial quality control system" reduced the age-related amyloid protein aggregates and improved the worms' fitness and lifespan.

The scientists then moved on to human muscle tissue, taken from aged subjects and IBM patients. Turning on the same mitochondrial quality control systems produced similar improvements in protein and mitochondrial homeostasis. The encouraging results led the researchers to test nicotinamide riboside in aged mice. The treatment also activated the mitochondrial defense systems and reduced the number and size of amyloid aggregates in different skeletal muscle tissues.

"Drugs that boost mitochondrial quality control could therefore be tested in the clinic to reverse these age-related proteotoxic aggregates and rejuvenate tissues," says Mario Romani, the first author of the study.

###

Other contributors
CHA University
Gwangju Institute of Science and Technology
Chungnam National University School of Medicine

Reference
Mario Romani, Vincenzo Sorrentino, Chang-Myung Oh, Hao Li, Tanes Imamura de Lima, Hongbo Zhang, Minho Shong, Johan Auwerx. NAD+ boosting reduces age-associated amyloidosis and restores mitochondrial homeostasis in muscle. Cell Reports 19 January 2021. DOI: 10.1016/j.celrep.2020.108660

The Cryonics Institutes 202nd Patient

Thursday, 21 January 2021 by System Administrator

8009001-digital-illustration-of-medical-caduceus-sign-in-3d-on-digital-background

Cryonics Institute Case Report for Patient Number 202

 

CI patient #202 was an 85 year old male from Canada. The patient was a CI member at the time of his death, but he did not have a contract or funding in place with CI.  The patient died on January 14th around 1pm.  The patient was put in dry ice.  The patient arrived at the CI facility at 8pm on January 15th.

 

The patient was then transferred to the computer controlled cooling chamber to cool to liquid nitrogen temperature.  The human vitrification program was selected and the time needed to cool the patient to liquid nitrogen temperature was five and a half days.  The reason the vitrification program was selected was because another patient that was perfused was going to be simultaneously cooled with this patient.  The patient was then placed in a cryostat for long-term cryonic storage.

New Covid Vaccine tested on Monkeys shows promise

Sunday, 25 October 2020 by System Administrator

Canstockphoto1996028

For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from the new coronavirus. The vaccine, an old-fashioned formulation consisting of a chemically inactivated version of the virus, produced no obvious side effects in the monkeys; human trials began on 16 April. And encouraging monkey results for other vaccines are close behind.

Researchers from Sinovac Biotech, a privately held Beijing-based company, gave two different doses of their COVID-19 vaccine to a total of eight rhesus macaques. Three weeks later, the group introduced SARS-CoV-2, the virus that causes COVID-19, into the monkeys' lungs. None developed a full-blown infection, and the monkeys given the highest dose of vaccine had the best response: Seven days after the animals received the virus, researchers could not detect it in their pharynx or lungs. Some of the lower dosed animals had a “viral blip” but also appeared to have controlled the infection, the Sinovac team reports in a paper published on 19 April on the preprint server bioRxiv.

In contrast, four control animals developed high levels of viral RNA and severe pneumonia. The results “give us a lot of confidence” that the vaccine will work in humans, says Meng Weining, Sinovac's senior director for overseas regulatory affairs.

“This is old school but it might work. What I like most is that many vaccine producers, also in lower–middle-income countries, could make such a vaccine,” says Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai.

But Douglas Reed of the University of Pittsburgh, who is developing and testing COVID-19 vaccines in monkeys, says the number of animals was too small to yield statistically significant results. In a manuscript in preparation, his team also raises concerns about the way the Sinovac team grew the stock of novel coronavirus used to challenge the animals, which may have evolved differences from the strains that infect humans. What's more, the monkeys are not a perfect model for COVID-19 as they don't develop some symptoms that kill many humans.

The study did address worries that partial protection by a vaccine could be dangerous. Earlier animal experiments with vaccines against the related coronaviruses that cause severe acute respiratory syndrome and Middle East respiratory syndrome had found that low antibody levels could lead to aberrant immune responses, enhancing the infection and damaging their lungs. But the Sinovac team did not find any evidence of lung damage in vaccinated animals that produced relatively low levels of antibodies, which “lessens the concern about vaccine enhancement,” Reed says. “More work needs to be done, though.”

To check the possibility that SARS-CoV-2 variants might thwart a vaccine, the Sinovac researchers mixed antibodies taken from monkeys, rats, and mice given their vaccine with strains of the virus isolated from patients in China, Italy, Switzerland, Spain, and the United Kingdom. The antibodies potently “neutralized” all the strains, which are “widely scattered on the phylogenic tree,” the researchers noted.

“This provides strong evidence that the virus is not mutating in a way that would make it resistant to a #COVID19 vaccine,” tweeted immunologist Mark Slifka of Oregon Health & Science University. “Good to know.”

An experimental vaccine made by the University of Oxford has also shown promise, although the data have not yet been published. Vincent Munster and his team at the Rocky Mountain Laboratories gave six monkeys the vaccine, which contains a gene for the surface protein of SARS-CoV-2 stitched into a harmless adenovirus that infects chimpanzees. Four weeks later, the researchers challenged the vaccinated animals and six controls. Seven days later, the vaccinated animals had a much stronger reduction of virus in their lower respiratory tracts than the controls. “The preliminary results look promising,” Munster says. “People just have to be patient.”

Sinovac recently started phase I human trials of its vaccine in Jiangsu province, north of Shanghai, which aim to gauge safety and immune responses in 144 volunteers. The company hopes to start phase II studies by mid-May that will assess the same endpoints but will enroll more than 1000 people.

If all goes well, Meng says, Sinovac will launch phase III efficacy trials that compare the vaccine with a placebo in thousands of people. Because of the low level of transmission now occurring in China, the company may run additional trials in harder hit countries. “We can't put all our eggs in one basket,” Meng says. Sinovac may also ask regulatory agencies in China and elsewhere for emergency authorization to give the vaccine to those at high risk of becoming infected, such as customs agents and police officers.

According to the World Health Organization, the Oxford vaccine and five others had entered human trials as of 26 April, and 82 candidates were in development. Most use versions of the SARS-CoV-2 surface protein, rather than whole, killed virus. Meng says how a vaccine is made will not ultimately matter. “In this pandemic situation, the most important thing is to make a vaccine, no matter what kind of vaccine it is, that's safe and effective as soon as possible.”

 

 

TOP